Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Accelerate Diagnostics ( (AXDX) ) has provided an update.
On May 8, 2025, Accelerate Diagnostics, Inc. filed for Chapter 11 bankruptcy, leading to a delisting notice from Nasdaq due to non-compliance with listing requirements. The company’s stock will be delisted from Nasdaq and is expected to trade on the OTC market under the symbol ‘AXDXQ’ starting May 15, 2025, although trading during the bankruptcy process is highly speculative and risky.
Spark’s Take on AXDX Stock
According to Spark, TipRanks’ AI Analyst, AXDX is a Underperform.
Accelerate Diagnostics faces significant financial challenges with declining revenues, high leverage, and negative cash flow, contributing to a low overall score. Technical indicators show bearish momentum, and valuation metrics highlight substantial risk. The Chapter 11 bankruptcy filing further exacerbates these risks, leading to a high-risk investment outlook with little upside potential.
To see Spark’s full report on AXDX stock, click here.
More about Accelerate Diagnostics
Accelerate Diagnostics, Inc. operates in the medical diagnostics industry, focusing on developing and commercializing innovative solutions for the rapid diagnosis of serious infections.
Average Trading Volume: 252,144
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.73M
Learn more about AXDX stock on TipRanks’ Stock Analysis page.